Latest Articles

Publication Date
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer - Oncodaily

NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer Oncodaily

Published: June 3, 2026, 3:15 a.m.
MGST3 Promotes Endometriosis Progression by Suppressing Ferroptosis.

Endometriosis (EMs) is characterized by dysregulated persistence and enhanced invasiveness of ectopic endometrial cells. Current treatment strategies remain limited by high recurrence rates and considerable adverse effects. Although iron overload …

Published: June 3, 2026, midnight
Pancreatic cancer breakthrough: New daily pill nearly doubles survival time in advanced patients - TheHealthSite

Pancreatic cancer breakthrough: New daily pill nearly doubles survival time in advanced patients TheHealthSite

Published: June 2, 2026, 10:11 a.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - MSN

Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer MSN

Published: June 2, 2026, 12:41 a.m.
Aberrant mitochondria in endometriosis: From pathogenic mechanisms to therapeutic opportunities.

Endometriosis affects about 10% of women of reproductive age and is a major cause of chronic pelvic pain and infertility, yet current therapies often fail to provide lasting relief. Mitochondrial …

Published: June 2, 2026, midnight
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - Medical Xpress

Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer Medical Xpress

Published: June 1, 2026, 8 p.m.
Epigenetics, Oxidative Stress, and the Microbiome in Endometriosis: Toward an Integrated Mechanistic Framework for Precision Medicine.

Endometriosis (EM) is a chronic, estrogen-dependent inflammatory disorder affecting approximately 6-10% of women of reproductive age in the general population and remains a major cause of chronic pelvic pain and …

Published: June 1, 2026, midnight
'White Days' play probes pain, silence and survival in women's reproductive health - standardmedia.co.ke

'White Days' play probes pain, silence and survival in women's reproductive health standardmedia.co.ke

Published: May 31, 2026, 12:58 p.m.
Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients - News-Medical

Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients News-Medical

Published: May 30, 2026, 2:16 a.m.
Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC - CancerNetwork

Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC CancerNetwork

Published: May 30, 2026, 12:40 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!